Dacarbazine medac 500 mg

DRUG4 trials

Sponsors

University College London, Erasca Inc., iOnctura SA, Oncopole Claudius Regaud

Conditions

Advanced Metastatic Ocular/Uveal MelanomaSoft Tissue SarcomaUnresectable or metastatic NRAS mutant cutaneous melanoma stage IA/IIA Hodgkin lymphoma

Phase 2

A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma

RecruitingCTIS2024-514333-37-00

iOnctura SAAdvanced Metastatic Ocular/Uveal Melanoma

Start: 2025-02-25Target: 43Updated: 2025-10-23

Phase 3

RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma

RecruitingCTIS2022-500031-37-00

University College London stage IA/IIA Hodgkin lymphoma

Start: 2024-04-08Target: 289Updated: 2025-06-23

Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized Soft Tissue Sarcoma

RecruitingCTIS2024-515384-62-00

Oncopole Claudius RegaudSoft Tissue Sarcoma

Start: 2020-10-09Target: 600Updated: 2025-12-23

A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]

RecruitingCTIS2024-511404-17-00

Erasca Inc.Unresectable or metastatic NRAS mutant cutaneous melanoma

Start: 2024-10-07Target: 294Updated: 2026-01-07